A new ADHD drug targets three brain chemicals instead of two. Here’s what that means

The Conversation · 🇦🇺 public Australia · Aug 13, 2026 · 910 words · By Jack Janetzki; Lisa Kalisch Ellett

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about A new ADHD drug targets three brain chemicals instead of two. Here’s what that means

The article provides an overview of centanafadine, a newly FDA-approved ADHD medication that targets dopamine, noradrenaline, and serotonin. It explains the drug's mechanism of action, compares it to other stimulants and antidepressants, and discusses its clinical trial results and current availability status in Australia.

Propaganda risk 0%

Claims checked 14

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center100%

Right0%

6 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

A new medicine for attention-deficit hyperactivity disorder (ADHD) has just entered the treatment toolbox: centanafadine, a once-a-day tablet sold under the brand name Simtriyo.

Why it matters

It has been approved in the United States for adults and children aged six years and older but isn’t yet available in Australia.

Common ground

How is it different to other ADHD medications?

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: A new ADHD drug targets three brain chemicals instead of two. Here’s what that means?
What evidence would most clearly confirm or weaken the claim that Another study compared the results of centanafadine trials with previous studies of medicines such as lisdexamfetamine and atomoxetine. It suggested centanafadine may cause less insomnia, anxiety, dry mouth and loss of appetite than lisdexamfetamine?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://theconversation.com/a-new-adhd-drug-targets-three-brain-chemicals-instea…

analyticsAnalysis

Propaganda Score

confidence: 100%

Low risk. This article shows minimal use of propaganda techniques.

fact_checkClaims Checked

eFinder analyzed this article and checked 14 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 6

schedule Pending 4

help Insufficient Evidence 2

verified Verified 1

verified Verified By Reference 1

schedule

Claim 1: “Another study compared the results of centanafadine trials with previous studies of medicines such as lisdexamfetamine and atomoxetine. It suggested centanafadine may cause less insomnia, anxiety, dry mouth and loss of appetite than lisdexamfetamine.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 2: “Centanafadine has not been approved by Australia’s Therapeutic Goods Administration (TGA). Nor has it been listed on the Pharmaceutical Benefits Scheme (PBS).”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 3: “The pharmaceutical company that made the drug called it a non-stimulant back in 2017. But the US Food and Drug Administration calls it a stimulant in the product information.”

VERIFIED

Evidence confirms the FDA classifies centanafadine as a CNS stimulant, contrasting with previous non-stimulant labels mentioned in the context of its development/classification.

menu_book

wikipedia NEUTRAL — Pembrolizumab, sold under the brand name Keytruda, is a humanized monoclonal antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy to treat many types of cancer. It is administere…
https://en.wikipedia.org/wiki/Pembrolizumab

menu_book

wikipedia NEUTRAL — The United States commissioner of food and drugs is the head of the Food and Drug Administration (FDA), an agency of the United States Department of Health and Human Services. The commissioner is nomi…
https://en.wikipedia.org/wiki/Commissioner_of_Food_and_Drugs

menu_book

wikipedia NEUTRAL — The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services (HHS). The FDA is responsible for protecting and promoting public health through…
https://en.wikipedia.org/wiki/Food_and_Drug_Administration

+ 3 more evidence sources

help

Claim 4: “One study in teenagers found ADHD symptoms improved within about a week of starting centanafadine.”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results regarding the specific timeline of symptom improvement (one week) in teenagers.

check_circle

Claim 5: “Most ADHD medicines are stimulants. These include dexamfetamine, lisdexamfetamine and methylphenidate.”

CORROBORATED

Multiple health sources (New Zealand, Australia, and healthdirect) confirm that dexamfetamine, lisdexamfetamine, and methylphenidate are stimulant ADHD medications.

travel_explore

web search NEUTRAL — The stimulant medicines methylphenidate, dexamfetamine and lisdexamfetamine are approved in New Zealand for the treatment of ADHD as part of a comprehensive treatment plan.
https://www.medsafe.govt.nz/committees/MARC/reports/201-3.2.…

travel_explore

web search NEUTRAL — The three main stimulants prescribed for ADHD in Australia are dexamfetamine, methylphenidate (sold under the brand names Ritalin and Concerta) and lisdexamfetamine (sold as Vyvanse).
https://theconversation.com/how-do-stimulants-actually-work-…

travel_explore

web search NEUTRAL — Stimulants are a class of drugs that make you feel more alert or energetic. They include drugs such as caffeine, some medicines, ice and cocaine.dexamfetamine, lisdexamfetamine, methylphenidate — for …
https://www.healthdirect.gov.au/stimulant-drugs

help

Claim 6: “the studies compared centanafadine with a placebo, rather than directly comparing it with medicines such as methylphenidate, dexamfetamine or atomoxetine.”

INSUFFICIENT EVIDENCE

While evidence confirms the trials were placebo-controlled, no provided evidence explicitly confirms the absence of head-to-head trials against methylphenidate, dexamfetamine, or atomoxetine.

check_circle

Claim 7: “It’s the first to affect three brain chemicals: noradrenaline (known as norepinephrine in the US), dopamine and serotonin.”

CORROBORATED

Sources describe it as a first-in-class medication targeting three brain chemicals: noradrenaline (norepinephrine), dopamine, and serotonin.

travel_explore

web search NEUTRAL — Centanafadine, sold under the brand name Simtriyo, is a medication used for the treatment of attention deficit hyperactivity disorder (ADHD). It is taken by mouth (orally).
https://en.wikipedia.org/wiki/Centanafadine

travel_explore

web search NEUTRAL — Jul 27, 2026 · Simtriyo (centanafadine) is a once-daily ADHD medicine for adults and children 6 and older. Learn how it works, dosage, side effects, and safety warnings.
https://www.drugs.com/simtriyo.html

travel_explore

web search NEUTRAL — Jan 29, 2026 · Centanafadine is a first-in-class NDSRI for ADHD, with FDA priority review and a PDUFA date of July 24, 2026. Four phase 3 trials showed significant efficacy of high-dose centanafadine …
https://www.pharmacytimes.com/view/centanafadine-for-treatme…

schedule

Claim 8: “The prescribing information also includes a warning about suicidal thoughts and behaviours.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 9: “It has been approved in the United States for adults and children aged six years and older but isn’t yet available in Australia.”

CORROBORATED

FDA approval for adults and children aged 6+ is confirmed by multiple sources. One source explicitly states it is not available in Australia.

travel_explore

web search NEUTRAL — Simtriyo FDA approval was granted on July 24, 2026, based on four Phase 3 clinical trials in children, adolescents, and adults, which demonstrated centanafadine produced statistically significant impr…
https://www.drugs.com/simtriyo.html

travel_explore

web search NEUTRAL — Centanafadine (Simtriyo) has been approved by the US Food and Drug Administration (FDA) for treatment of attention-deficit/hyperactive disorder (ADHD) in adults and children aged 6 and older (>20 kg).…
https://www.psychiatrictimes.com/view/fda-approves-centanafa…

travel_explore

web search NEUTRAL — There’s also Simtriyo (centanafadine) , FDA-approved on 24 July 2026 as the first of a new class. It isn’t available even in the United States yet — it’s awaiting scheduling — and it carries a boxed w…
https://adhdmums.com.au/adhd-medications-not-available-austr…

check_circle

Claim 10: “Centanafadine was tested in four large phase-3 clinical trials before it was approved in the US.”

CORROBORATED

Multiple sources, including Drugs.com, explicitly state that FDA approval was supported by results from four Phase 3 clinical trials.

travel_explore

web search NEUTRAL — Results of Phase 3 Clinical Trials. A set of randomized, double-blind, placebo-controlled trials analyzed centanafadine’s efficacy in 480 children and 459 adolescents.
https://www.additudemag.com/centanafadine-simtriyo-approved-…

travel_explore

web search NEUTRAL — The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for priority review of centanafadine, an investigational once-daily extended-release capsule for the treatment of AD…
https://www.hcplive.com/view/fda-accepts-nda-priority-review…

travel_explore

web search NEUTRAL — FDA approval history for Simtriyo (centanafadine) used to treat ADHD.FDA approval of Simtriyo was supported by results from four randomized, double-blind, placebo-controlled Phase 3 clinical trials.
https://www.drugs.com/history/simtriyo.html

verified

Claim 11: “Strattera is the brand name for atomoxetine.”

VERIFIED BY REFERENCE

Wikipedia and drug databases explicitly state that Strattera is the brand name for atomoxetine.

travel_explore

web search NEUTRAL — Aug 27, 2026 · Strattera is a treatment for attention deficit hyperactivity disorder (ADHD) to help improve attention and reduce hyperactivity and impulsiveness. Strattera works by increasing levels o…
https://www.drugs.com/strattera.html

travel_explore

web search NEUTRAL — Atomoxetine is manufactured, marketed, and sold in the United States as the hydrochloride salt (atomoxetine HCl) under the brand name Strattera by Eli Lilly and Company, the original patent -filing co…
https://en.wikipedia.org/wiki/Atomoxetine

travel_explore

web search NEUTRAL — Jul 8, 2024 · Overview: Atomoxetine is used to help with attention deficit and hyperactivity disorder (ADHD) by improving focus and reducing impulsivity and hyperactivity. It works by increasing a nat…
https://www.webmd.com/drugs/atomoxetine-strattera

check_circle

Claim 12: “Atomoxetine mainly increases the amount of noradrenaline available in the brain. It has much less effect on dopamine and serotonin.”

CORROBORATED

Sources indicate atomoxetine primarily focuses on norepinephrine (noradrenaline) with minimal effects on dopamine.

travel_explore

web search NEUTRAL — 1.1. Noradrenaline and dopamine levels increased in the PFC¶. In the laboratory, atomoxetine appears to act primarily as a noradrenaline (transporter) reuptake inhibitor. The results in vivo differ fr…
https://www.adxs.org/en/page/190/atomoxetine-for-adhd

travel_explore

web search NEUTRAL — While stimulants also increase dopamine levels in addition to norepinephrine, leading to feelings of euphoria and potential for abuse, atomoxetine primarily focuses on norepinephrine with minimal effe…
https://brainly.com/question/50842382

travel_explore

web search NEUTRAL — Testosterone has an effect on dopamine and cognitive functioning as well. ADHD treatment NC inverted U-shaped dose-response curve showing how dopamine and norepinephrine levels affect prefrontal corte…
https://thebh.us/blog/adhd-neuroscience-treatment-emerging-r…

schedule

Claim 13: “The most common side effects reported with centanafadine include reduced appetite, insomnia, dry mouth and headache.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 14: “centanafadine, a once-a-day tablet sold under the brand name Simtriyo.”

CORROBORATED

Multiple sources confirm centanafadine is sold under the brand name Simtriyo and is a once-daily medication (extended-release capsule).

travel_explore

web search NEUTRAL — Centanafadine belongs to a new class of ADHD medicines. It’s the first to affect three brain chemicals: noradrenaline (known as norepinephrine in the US), dopamine and serotonin. Others usually only t…
https://www.psypost.org/the-science-behind-simtriyo-the-firs…

travel_explore

web search NEUTRAL — Formulation: Centanafadine (SIMTRIYO®) is formulated as a once-daily extended-release capsule.TheBrief Treatment-induced menopause (TIM) is an under-recognized health outcome for women with breast can…
https://thebrief.health/a-new-frontier-in-adhd-pharmacothera…

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.